Table 1 Patients and tumours’ characteristics, treatments and outcomes
From: Use of trastuzumab in treating breast cancer during pregnancy: a systematic review and meta-analysis
Characteristic | Goodyer et al. [7] | Waterston et al. [1] | Azim Jr et al. [8] | Min et al. [9] | Pant et al. [10] |
|---|---|---|---|---|---|
Stage | IV | NR | IIB | NR | IV |
Treatment | Trastuzumab | Trastuzumab | Trastuzumab | Trastuzumab | Trastuzumab |
Receptor (ER\PR\HER-2) | (−)(−)(+) | (−)(−)(+) | (−)(−)(+) | (−)(−)(+) | (−)(−)(+) |
Age at pregnancy (y) | 33 | 30 | 29 | 32 | 32 |
GA (week) | 14 | 3 | 3 | 17 | 14 |
Trastuzumab | |||||
 Schedule (weeks) | 1 | 3 | 3 | 3 | 3 |
 Total dose | NR | 1259 mg | NR | 600 mg | 4200 mg |
 GA (week) | 14–29 | 0–3 | 0–1 | 0–17 | 0–32 |
 Chemotherapy | No | No | No | No | No |
 Pregnancy/fetal complication | No | No | No | No | Anhydramnios |
Delivery | |||||
 Weeks | 29 | NR | 39 | 38 + 5 | 32 + 1 |
 Mode | cs | Vaginal | cs | Vaginal | Vaginal |
New born | |||||
 Weight (g) | 1220 | NR | 3550 | 3570 | 1810 |
 Apgar scores | NR | NR | NR | 9, 10 | normal |
 Complications | Respiratory distress syndrome | No | No | No | No |
 Follow-up (months) | Minimal tightness of the left Achilles tendon at 36 months | NR | Healthy at 14 months | NR | healthy at 60 months |
Characteristic | Pianca et al. [11] | Rasenack et al. [12] | Bader et al. [13] | Mandrawa et al. [14] | Roberts et al. [15] |
|---|---|---|---|---|---|
Stage | IIA | IV | IV | IV | IIB |
Treatment | Trastuzumab | Trastuzumab | 46 Gy (cervical vertebra) with shielding + trastuzumab + paclitaxel | Trastuzumab | Trastuzumab |
Receptor (ER\PR\HER-2) | (−)(−)(+) | (−)(−)(+) | (−)(+)(+) | (−)(−)(+) | (−)(−)(+) |
Age at pregnancy (y) | 30 | 29 | 38 | 28 | 36 |
GA (week) | 28 | NR | 17 | 12 | 17 |
Trastuzumab | |||||
 Schedule (weeks) | 3 | 3 | 3 | 3 | 3 |
 Total dose | NR | NR | NR | 3510 mg | NR |
 GA (week) | 0–28 | 0–24 | 25–28 | 0–27 | 4–21 |
 Chemotherapy | No | No | Paclitaxel (25 week) | No | No |
 Pregnancy/fetal complication | Anhydramnios | Anhydramnios | Anhydramnios, fetal renal failure | Anhydramnios | Decline of cardiac ejection fraction |
Delivery | |||||
 Weeks | 37 | 36 | 32 | 37 | 37 |
 Mode | Vaginal | CS | CS | Vaginal | Vaginal |
New born | |||||
 Weight (g) | 2535 | NR | 1460 | 3060 | 3200 |
 Apgar scores | 4, 8 | NR | NR | NR | NR |
 Complications | No | No | Signs of bacterial sepsis (hypotension, transient renal failure, respiratory failure, positive laboratory findings | Transient tachypnoea at birth | Mild transient tachypnoea |
 Follow-up (months) | Healthy at 84 months | Healthy at 60 months | Healthy at 3 months | Healthy at 28 months | NR |
Characteristic | Witzel et al. [16] | Shrim et al. [17] | Beale et al. [18] | Warraich et al. [19] | |
|---|---|---|---|---|---|
Stage | IV | IV | NR | NR | |
Treatment | Trastuzumab | Trastuzumab | Trastuzumab + tamoxifen | Trastuzumab + tamoxifen + goserelin | |
Receptor (ER\PR\HER-2) | (+)(+)(+) | (−)(−)(+) | (+)(+)(+) | (+)(+)(+) | |
Age at pregnancy (y) | 34 | 32 | 29 | 35 | |
GA
(week) | 23 | 5 | 23 | 7 | |
Trastuzumab | |||||
 Schedule (weeks) | 3 | 3 | 3 | 3 | |
 Total dose | NR | 3200 mg | NR | 3675 mg | |
 GA (week) | 0–26 | 0–24 | 0–22 | 7–31 | |
 Chemotherapy | No | No | No | No | |
 Pregnancy/fetal complication | Oligohydramnios and vaginal bleeding | Asymptomatic low ejection fraction (weeks 18, 24) | Anhydramnios | Anhydramnios | |
Delivery | |||||
 Weeks | 27 | 37 | 31 | 34 | |
 Mode | CS | CS | CS | NR | |
New born | |||||
 Weight (g) | 1015 | 2600 | 1590 and 1705 | NR | |
 Apgar scores | 8, 7 | 9, 10 | 5, 8 and 8, 10 | NR | |
 Complications | Respiratory failure, strong capillary link syndrome, persisting infections, necrotizing enterocolitis | Transient tachypnea at birth | Twin A: chronic lung disease and renal failure, Twin B: creatinine elevation and respiratory distress syndrome at birth | Severe pulmonary hypoplasia and atelectasis | |
 Follow-up (months) | Dead at 5.25 months | Healthy at 2 months | Twin A:Dead from respiratory arrest at 0.25 months, TwinB:Healthy at 0.25 months | Dead within 40 min at birth | |
Characteristic | Watson et al. [20] | Fanale et al. [21] | Sekar et al. [22] | Weber et al. [23] | |
|---|---|---|---|---|---|
Stage | IIIB | IV | IV | IV | |
Treatment | Trastuzumab | Vinorelbine + trastuzumab | Docetaxel + trastuzumab | Trastuzumab | |
Receptor (ER\PR\HER-2) | (−)(−)(+) | (−)(−)(+) | (−)(−)(+) | NR | |
Age at pregnancy (y) | 28 | 27 | 28 | 32 | |
GA (week) | 23 | 27 | 20 | NR | |
Trastuzumab | |||||
 Schedule (weeks) | 3 | 1 | 3 | 3 | |
 Total dose | 3480 mg | 2700 mg | 1385 mg | NR | |
 GA (week) | 0–20 | 27–34 | 23–27 | 0–23 | |
 Chemotherapy | No | Vinorelbine (at 27 week) | Docetaxel (at 23 week) | No | |
 Pregnancy/fetal complication | Anhydramnios and small fetal bladder (23 weeks) | Anhydramnios | Anhydramnios | Anhydramnios | |
Delivery | |||||
 Weeks | 37 | 34 | 36 | 27 | |
 Mode | Vaginal | Vaginal | CS | CS | |
New born | |||||
 Weight (g) | 2960 | 2580 | 2230 | NR | |
 Apgar scores | 8, 9 | 9, 9 | 7, 9 | NR | |
 Complications | No | No | No | Multiple prematurity related problems at birth | |
 Follow-up (months) | Healthy at 6 months | Healthy at 6 months | NR | Dead at 4 months | |
Characteristic | Gottschalk et al. [24] | El-Safadi et al. [25] | Andrade et al. [26] | Aktoz et al. [27] | |
|---|---|---|---|---|---|
Stage | NR | IV | III | IV | |
Treatment | Docetaxel + carboplatin + trastuzumab | Vinorelbine + trastuzumab + ibandronate | Trastuzumab | Docetaxel + trastuzumab | |
Receptor (ER\PR\HER-2) | (+)(+)(+) | (−)(−)(+) | NR | (−)(−)(+) | |
Age at pregnancy (y) | 38 | 32 | 31 | 37 | |
GA (week) | 11 | 29 | 9 | 22 | |
Trastuzumab | |||||
 Schedule (weeks) | 1 | 3 | 3 | 3 | |
 Total dose | NR | NR | 4400 mg | 2293 mg | |
 GA (week) | 14–17 | 30–33 | 0–32 | 22–34 | |
 Chemotherapy | Docetaxel + carboplatin (at 17 week) | Vinorelbine + ibandronate (at 30 week) | No | Docetaxel (at 22 week) | |
 Pregnancy/fetal complication | Anhydramnios, intrauterine growth restriction, fetal renal insufficiency | Anhydramnios | Anhydramnios | No | |
Delivery | |||||
 Weeks | 33 | 33 | 32+2 | 35+3 | |
 Mode | CS | CS | CS | CS | |
New born | |||||
 Weight (g) | NR | 1990 | 1655 | 2850 | |
 Apgar scores | NR | 8, 9 | 4, 10 | 8, 8 | |
 Complications | Dystrophic premature neonate at birth | No | Respiratory distress syndrome and a pulmonary infection | Transient renal insufficiency | |
 Follow-up (months) | NR | Healthy at 12 months | Healthy at 84 months | Healthy at 5 days | |